This Review traces the development of chimeric antigen receptor (CAR) T cell therapy from foundational immunology to approved products, highlighting clinical successes, engineering advances, safety strategies and ongoing challenges in extending durable responses beyond haematological malignancies.

Nature Reviews Immunology, Published online: 02 July 2026; doi:10.1038/s41577-026-01322-1This Review traces the development of chimeric antigen receptor (CAR) T cell therapy from foundational immunology to approved products, highlighting clinical successes, engineering advances, safety strategies and ongoing challenges in extending durable responses beyond haematological malignancies.

Nature Reviews Immunology, Published online: 02 July 2026; doi:10.1038/s41577-026-01322-1This Review traces the development of chimeric antigen receptor (CAR) T cell therapy from foundational immunology to approved products, highlighting clinical successes, engineering advances, safety strategies and ongoing challenges in extending durable responses beyond haematological malignancies.

Hind Rafei: Thanks DoD Ovarian Cancer Research Program for Support / cancer, Hind Rafei, MD Anderson Cancer Center, OncoDaily, Oncology

The University of Texas MD Anderson Cancer Center today announced its 10th cohort of Andrew Sabin Family Fellows, comprised of 10 early career cancer researchers. Created to provide a dedicated source of funding for emerging clinician and scientist leaders, the Sabin Family Fellowship supports groundbreaking research that fuels MD Anderson’s mission to end cancer.

The transcription factor CREM is a pivotal regulator of NK cell function, making CREM a valuable target to increase the efficacy of anticancer immunotherapies based on this cell population and chimeric antigen receptors.

The transcription factor CREM is a pivotal regulator of NK cell function, making CREM a valuable target to increase the efficacy of anticancer immunotherapies based on this cell population and chimeri...